Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

POSEIDA THERAPEUTICS, INC.

(PSTX)
  Report
Real-time Estimate Cboe BZX  -  02:59 2022-09-26 pm EDT
3.025 USD   +0.17%
09/07Poseida Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
PR
09/07Poseida Therapeutics, Inc. : Other Events (form 8-K)
AQ
08/11Poseida Therapeutics : Provides Updates and Financial Results for the Second Quarter of 2022 - Form 8-K
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Poseida Therapeutics Shares Soar After Roche Collaboration

08/03/2022 | 10:22am EDT

By Colin Kellaher


Shares of Poseida Therapeutics Inc. surged more than 45% in early trading Wednesday after the biopharmaceutical company said it inked a lucrative collaboration and agreement with Swiss drugmaker Roche Holding AG targeting cancers that affect the blood.

Poseida said it could pick up payments topping $6 billion over the life of the deal, including $110 million up front and up to $110 million in near-term milestones and other payments.

The San Diego company and Roche plan to develop allogeneic CAR-T therapies against targets in multiple myeloma, B-cell lymphomas and other hematologic indications.

Poseida, which reported a cash and equivalents balance of $183.5 million as of March 31, last year signed a collaboration and license agreement potentially worth billions of dollars with Japan's Takeda Pharmaceutical Co. focused on developing nonviral, in-vivo gene-therapy programs, including Poseida's hemophilia A program.

Poseida shares were recently changing hands at $3.55, up 46%.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

08-03-22 1021ET

Stocks mentioned in the article
ChangeLast1st jan.
POSEIDA THERAPEUTICS, INC. -1.82% 2.965 Delayed Quote.-55.65%
ROCHE HOLDING AG -1.10% 305.9 Delayed Quote.-18.41%
TAKEDA PHARMACEUTICAL COMPANY LIMITED -1.29% 3740 Delayed Quote.20.78%
All news about POSEIDA THERAPEUTICS, INC.
09/07Poseida Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Confer..
PR
09/07Poseida Therapeutics, Inc. : Other Events (form 8-K)
AQ
08/11Poseida Therapeutics : Provides Updates and Financial Results for the Second Quarter of 20..
PU
08/11POSEIDA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
08/11Poseida Therapeutics, Inc. : Results of Operations and Financial Condition (form 8-K)
AQ
08/11Poseida Therapeutics, Inc. Announces Program Updates
CI
08/11Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q2 Revenue $2.7M
MT
08/11Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2..
PR
08/11Poseida Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Mont..
CI
08/09Piper Sandler Adjusts Price Target on Poseida Therapeutics to $11 From $9, Reiterates O..
MT
More news
Analyst Recommendations on POSEIDA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 48,2 M - -
Net income 2022 -200 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,28x
Yield 2022 -
Capitalization 250 M 250 M -
Capi. / Sales 2022 5,19x
Capi. / Sales 2023 3,07x
Nbr of Employees 290
Free-Float 70,1%
Chart POSEIDA THERAPEUTICS, INC.
Duration : Period :
Poseida Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends POSEIDA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 3,02 $
Average target price 16,75 $
Spread / Average Target 455%
EPS Revisions
Managers and Directors
Mark J. Gergen President, Chief Executive Officer & Director
Johanna M. Mylet Chief Financial Officer
Eric M. Ostertag Executive Chairman
Harry J. Leonhardt Secretary & Chief Compliance Officer
Kristin Martin Chief People & Administration Officer
Sector and Competitors
1st jan.Capi. (M$)
POSEIDA THERAPEUTICS, INC.-55.65%250
GILEAD SCIENCES, INC.-13.43%78 787
REGENERON PHARMACEUTICALS, INC.10.42%74 550
VERTEX PHARMACEUTICALS29.08%72 693
BIONTECH SE-50.21%31 192
WUXI APPTEC CO., LTD.-41.46%28 154